west china medical publishers
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search


find Author "SUN Xin" 80 results
  • Markov Modelling in Healthcare Economic Evaluations

    Release date:2016-09-07 02:14 Export PDF Favorites Scan
  • Lamivudine for HBeAg Positive Chronic Hepatitis B: A Meta-analysis of Randomized Controlled Trials

    Objective To assess the efficacy of lamivudine in patients with HBeAg positive chronic hepatitis B.Methods MEDLINE, SCI, Current Content Connect, The Cochrane Library, and Chinese Biomedical Database were searched from the beginning to September 2005, and the references of eligible studies were manually screened. R.andomized controlled trials comparing lamivudine with non-antiviral interventions ( placebo, no treatment and standard care ) in patients with chronic hepatitis B were eligible for inclusion. Two investigators independently assessed the quality and extracted the data. Heterogeneity was examined by Chi-square test. Fixed and random effect meta-analysis were used to pool the data. Subgroup analyses were used in treatment course. Results Eleven R.CTs were included ( n = 1 237 ). All reported the effect of lamivudine (100 mg/d) , and one of them included lamivudine (25 mg/d). The treatment duration of 52 weeks and less than 26 weeks were reported in eight and three RCTs, respectively. Six RCTs adequately applied randomization, while other five RCTs were not reported in detail. Four RCTs adequately enforced allocation concealment, five RCTs enforced blinding bitterly. The others were not reported in detail. It was found by meta-analysis that, compared with the control, lamivudine (100 mg/d, 52 W) could significantly clear HBeAg [42.6% vs. 13% , RR 3.20, 95% CI (2.33, 4. 38)] and clearHBVDNA [71.78% vs. 20, 36%, RR3.42, 95%CI (2.80,4.19)], normalize ALT [65% vs. 34.9%, RR1.91, 95%CI (1.64,2.21)], achieve HBeAgseroconversion [16.1% vs. 7.29% , RR2.12, 95%CI (1.24,3.80) ] and histology response [57. 9% vs. 26.2%, RR 2. 17, 95% CI ( 1.67,2.81 ) ] ; Lanfivudine (100 mg/ d, 12 W) could effectively clear HBV DNA [ 50.7% vs 3.92% , RR 8.68, 95% CI (1.72,43.74 ) ] , but was not effective in loss of HBeAg, HBeAg seroconversion and normalization of ALT, Lamivudine (25 mg/d) could effectively clear HBV DNA [97.7% vs. 22.2% , RR 4.41, 95% CI (2.86,6.79) ] and improve histology response [59.3% vs. 30% , RR1.98, 95% CI (1.31,2.99 ) ], but was not effective in HBeAg seroconversion. Conclusions Lamivudine (100 mg/ d) is effective in clearing HBV DNA and HBeAg, normalizing ALT and achieving HBeAg seroconversion.

    Release date:2016-08-25 03:34 Export PDF Favorites Scan
  • Using Individual Patients Data in Meta-analyses for Assessing Effects of Health care Interventions

    Individual patient data meta-analyses are conducted through development of collaboration with trial investigators, central collection and checking of individual patient data of all eligible trials, and pooling of patient data to produce the best estimate of effects of health care interventions. They ensure study data to be update, accessible, reliable and complete so as to minimize the risk of bias, and are the gold standard of systematic reviews addressing effects of health care interventions. Meta-analyses using individual patient data enable higher flexibility of data analyses and more completeness and balance of results interpretation. The study conduct differs between individual patient data versus conventional meta-analyses. This article discussed the steps of conducting individual patient data meta-analyses.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • Risk Monitoring of Biologicals Derived from Adverse Reaction Management of Natalizumab: A Systematic Review Based on Serious Adverse Reaction Reports and Related Regulatory Documents

    Objective To analyze the withdrawal reason of natalizumab in depth based on the serious adverse reaction reports and approval channel, and to provide decision references for more safe and effective report method of other biologicals. Methods We searched MEDLINE, EMbase, and the official websites of Food and Drug Administration (FDA) for case reports, approval channel, and the relevant information of drug marketing or withdrawal. Results Four case reports and fourteen official reports were included. Three cases of progressive multifocal leukoencephalopathy (PML) were reported in the clinical trials after natalizumab’s initially approval with two dead and one disabled, which could be retrieved by hemodialysis (2 cases hitherto). Consequently, multiple sclerosis (MS) patients were willing to bear the risk. Two cases of natalizumab-related PML (0.06‰) were confirmed in 32 000 patients without death report after two years of its remarketing, in July 2008. Another PML patient was reported in October 2008. Because of its non-substitutability for treating MS and Crohn disease (CD), FDA announced that patients could still use natalizumab under the close monitoring. Conclusion (1) The most serious adverse reaction of treating MS and CD with natalizumab is PML, but it can be preventable and curable now. The monitoring findings of efficacy and adverse reaction during the postmarketing indicate that the review system is perfect and practicable relatively, and can give references for other high-risk drugs on the fast or standard approval channel, for example, Chinese medicine injection can draw lessons from it. (2) The remarketing of natalizumab not only provide significant risk management precedent for other drug-development firms, but also brings hope to the remarketing or relaunching clinical trials for the suspected sideeffect drugs. (3) Because of the fast-track reviewing of natalizumab and the overlap between the research of Good Clinical Practice (GCP) and the post-marketing evaluation, we should continue to track the information and provide new evidence.

    Release date:2016-09-07 02:08 Export PDF Favorites Scan
  • Systematic Review of Economic Analyses: Methods and Challenges

    Based on the principles and methods of systematic review of randomized controlled clinical trials, systematic review of economic analyses can integrate information from multiple economic studies which focus on the same clinical questions. It can also provide important insights by systematically examining how differences among studies lead to different results. Generally, there are seven steps to conduct such a review: 1) formulating questions; 2) establishing eligibility criteria; 3) searching and selecting eligible economic analyses; 4) assessing the validity of economic analyses; 5) acquiring data; 6) analyzing and synthesizing data; and 7) presenting results. Owing to the specificity of economic analyses, many methodological challenges exist, including the varieties of economic models, analytic perspectives, time horizons, and uncertainty and sensitivity analysis among different economic analyses. This may cause difficulties for critical assessment of the economic analyses.

    Release date:2016-09-07 02:11 Export PDF Favorites Scan
  • Methods for Socio-Economic Evaluation of Marketed MedicinesⅢ: Factors Affecting Methodological Quality and Transferability

    Methodological quality and transferability will be important issues for the credibility and usefulness of both published studies and administrative methods for evaluating the socio-economic value of marketed medicines in China. This paper critically examines factors commonly contributing to, or inhibiting, the quality and transferability of socio-economic evidence of the value of medicines, with specific reference to the Chinese community. It discusses appropriate approaches to design, performance, and reporting of published economic evaluation studies, as well as guides on assessment of quality of economic evaluations and recommends two internationally established methods that may be suitable for training in this setting.

    Release date:2016-09-07 02:18 Export PDF Favorites Scan
  • Cost Analysis in Clinical Trials

    Economic evaluation used alongside clinical trials has become a hot spot in the development of clinical studies. The definition and classification of the cost were introduced in this article. The ways to conduct cost analysis in clinical trials were introduced systematically, including the identification, collection and analysis of the data of costs, and the concern of the analysis.

    Release date:2016-09-07 02:27 Export PDF Favorites Scan
  • Reporting intervention detail, improving usability of systematic reviews

    In recent years, an increasing amount of systematic reviews have been published; however, few reviews adequately considered and reported details of interventions, which not only limited the usability of systematic reviews but also wasted resource. In order to improve reporting of intervention details in systematic reviews, BMJ recently published recommendations. This paper interprets the recommendations to improve usability of systematic reviews.

    Release date:2018-01-20 10:09 Export PDF Favorites Scan
  • Evidence-based traditional Chinese medicine: present and future

    Evidence-based Chinese medicine (EBCM) is one of the innovative achievements in the development of evidence-based medicine (EBM) in China. The EBCM has made initial progress: the evidence-based scientific decision-making model has become popular; a series of key technologies for evidence-based evaluation and research of traditional Chinese medicine (TCM) have been established; several technical specifications have been formulated in line with international standards; clinical evidence database of TCM has been established; a number of high quality clinical trials have been published in internationally renowned journals; and the International Forum on Evidence based Chinese Medicine(EBCM) has become a brand conference. Difficulties in EBCM development mainly involve: lack of high quality clinical evidence, difficulty in producing evidence, and decentralization of research team. Based on opportunities and challenges of the development of TCM, this article proposed the short-term and long-term goals, implementation paths and five key directions for the development of EBCM in the future, and puts forward three suggestions for further development of EBCM.

    Release date:2019-06-24 09:18 Export PDF Favorites Scan
  • Statistical methods in pragmatic randomized controlled trials (I): addressing non-compliance

    In the study of real-world data, the pragmatic randomized controlled trial can provide the optimal evidence for clinical decisions. Although randomization protects against confounding, post-randomization confounding may still arise due to non-compliance. Traditional intention-to-treat analysis will drift apart from true estimation and lead to deviation of clinical decisions. Meanwhile, the alternative traditional methods would subject to bias and confounding. Thus, new methods are required for revolution, i.e., instrument variable method and modern per-protocol analysis. Our study reviews the defects of traditional methods in pragmatic randomized controlled trials, and then refers to two new methods with a detailed discussion of strengths and weaknesses. We aim to provide researches with insights on choosing the statistical methods for pragmatic trial.

    Release date:2021-02-05 02:57 Export PDF Favorites Scan
8 pages Previous 1 2 3 ... 8 Next